Converting Tumoral PD-L1 into a 4-1BB Agonist for Safer and More Effective Cancer Immunotherapy

被引：4

作者：

Li, Zihai ^{[1
,2
]}

Azar, Joseph H. ^{[1
,2
]}

Rubinstein, Mark P. ^{[1
,2
]}

机构：

[1] Ohio State Univ, Div Med Oncol, Dept Internal Med, Columbus, OH USA

[2] Ohio State Univ, James Comprehens Canc Ctr, Plotonia Inst Immunooncol, 460 W 12th Ave,BRT 510,Biomed Res Tower, Columbus, OH 43210 USA

来源：

CANCER DISCOVERY | 2022年 / 12卷 / 05期

关键词：

D O I：

10.1158/2159-8290.CD-22-0219

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Dose-limiting toxicities are thought to temper the efficacy of single-agent 4-1BB agonists. To overcome this hurdle, in this issue of Cancer Discovery, Muik and colleagues report preclinical and clinical studies describing a first-in-class bispecific fusion protein targeting 4-1BB and PD-L1.

引用

页码：1184 / 1186

页数：3

共 10 条

[1] Antonarelli G, PHARMACEUTICALS-BASE, V14, P884
[2] Antibodies to Costimulatory Receptor 4-1BB Enhance Anti-tumor Immunity via T Regulatory Cell Depletion and Promotion of CD8 T Cell Effector Function
Buchan, Sarah L.
Dou, Lang
Remer, Marcus
Booth, Steven G.
Dunn, Stuart N.
Lai, Chester
Semmrich, Monika
Teige, Ingrid
Martensson, Linda
Penfold, Christine A.
Chan, H. T. Claude
Willoughby, Jane E.
Mockridge, C. Ian
Dahal, Lekh N.
Cleary, Kirstie L. S.
James, Sonya
Rogel, Anne
Kannisto, Paivi
Jernetz, Mats
Williams, Emily L.
Healy, Eugene
Verbeek, J. Sjef
Johnson, Peter W. M.
Frendeus, Bjorn
Cragg, Mark S.
Glennie, Martin J.
Gray, Juliet C.
Al-Shamkhani, Aymen
Beers, Stephen A.
[J]. IMMUNITY, 2018, 49 (05) : 958 - +
[3] Immunotherapy targeting 4-1BB: mechanistic rationale, clinical results, and future strategies
Chester, Cariad
Sanmamed, Miguel F.
Wang, Jun
Melero, Ignacio
[J]. BLOOD, 2018, 131 (01) : 49 - 57
[4] An Update on Anti-CD137 Antibodies in Immunotherapies for Cancer
Dinh-Toi Chu
Nguyen Duy Bac
Khanh-Hoang Nguyen
Nguyen Le Bao Tien
Vo Van Thanh
Vu Thi Nga
Vo Truong Nhu Ngoc
Duong Thi Anh Dao
Le Ngoc Hoan
Nguyen Phuc Hung
Nguyen Thi Trung Thu
Van-Huy Pham
Le Nguyen Vu
Thuy Anh Vu Pham
Raj, Deepak B. Thimiri Govinda
[J]. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2019, 20 (08)
[5] Principles and Current Clinical Landscape of Multispecific Antibodies against Cancer
Elshiaty, Mariam
Schindler, Hannah
Christopoulos, Petros
[J]. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2021, 22 (11)
[6] CD137 as an Attractive T Cell Co-Stimulatory Target in the TNFRSF for Immuno-Oncology Drug Development
Hashimoto, Kenji
[J]. CANCERS, 2021, 13 (10)
[7] Preclinical Characterization and Phase I Trial Results of a Bispecific Antibody Targeting PD-L1 and 4-1BB (GEN1046) in Patients with Advanced Refractory Solid Tumors
Muik, Alexander
Garralda, Elena
Altintas, Isil
Gieseke, Friederike
Geva, Ravit
Ben-Ami, Eytan
Maurice-Dror, Corinne
Calvo, Emiliano
LoRusso, Patricia M.
Alonso, Guzman
Rodriguez-Ruiz, Maria E.
Schoedel, Kristina B.
Blum, Jordan M.
Sanger, Bianca
Salcedo, Theodora W.
Burm, Saskia M.
Stanganello, Eliana
Verzijl, Dennis
Vascotto, Fulvia
Sette, Angelica
Quinkhardt, Juliane
Plantinga, Theo S.
Toker, Aras
van den Brink, Edward N.
Fereshteh, Mark
Diken, Mustafa
Satijn, David
Kreiter, Sebastian
Breij, Esther C. W.
Bajaj, Gaurav
Lagkadinou, Eleni
Sasser, Kate
Tureci, Ozlem
Forssmann, Ulf
Ahmadi, Tahamtan
Sahin, Ugur
Jure-Kunkel, Maria
Melero, Ignacio
[J]. CANCER DISCOVERY, 2022, 12 (05) : 1248 - 1265
[8] Nie Siwei, 2020, Antib Ther, V3, P18, DOI 10.1093/abt/tbaa003
[9] CD137+ T-Cells: Protagonists of the Immunotherapy Revolution
Ugolini, Alessio
Nuti, Marianna
[J]. CANCERS, 2021, 13 (03) : 1 - 16
[10] Immune regulation by 4-1BB and 4-1BBL: complexities and challenges
Wang, Chao
Lin, Gloria H. Y.
McPherson, Ann J.
Watts, Tania H.
[J]. IMMUNOLOGICAL REVIEWS, 2009, 229 : 192 - 215

← 1 →